Form 4: Recursion Pharmaceuticals Director Sells Shares

Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock via a Rule 10b5-1 trading plan.

Summary

• Director Christopher Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock.
• Following the conversion, the director sold 40,000 shares of Class A Common Stock at a price of $3.61 per share.
• The transaction was executed on April 22, 2026, pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
• Post-transaction, the director maintains direct ownership of 906,556 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 program, which is standard for corporate insiders.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.

Negatives

• The transaction represents a divestment of equity by a company director.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice in the biotechnology sector, often used for liquidity purposes rather than reflecting a change in long-term outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is standard practice for executives at publicly traded biotech firms like Recursion Pharmaceuticals to manage personal portfolios.
• The transaction size is relatively small compared to the director's total holdings, which is consistent with routine portfolio rebalancing.

Related Party Transactions

• The director maintains interests in LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, which hold additional shares of the company.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the director's total beneficial ownership.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Biotech, Equity Sale